english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

"Faces of Mediator", a new book published by Prescrire

Les Visages du Mediator It was after seeing the French film "La Fille de Brest", an adaptation of the book by pulmonologist and whistle-blower Irène Frachon, that the photographer Marc Dantan first got the idea of taking portraits of the victims of Mediator° (benfluorex), in the hope that "bringing faces into the light could perhaps raise awareness of the silent suffering". That was the beginning of this book, which presents in 208 pages some 180 photographs, along with a foreword by Irène Frachon, a summary of the history of the Mediator° disaster, and an afterword by Prescrire. Texts in French and English.
1 October 2019

Paracetamol: patients need to be more aware of the harms

In France, 20% of patients seem to be unaware that paracetamol is toxic at high doses, especially to the liver, and around 30% are unaware that alcohol aggravates this toxicity.
1 October 2019

Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha°) and alirocumab (Praluent°)

In patients who have already had a cardiovascular event, the addition of evolocumab or alirocumab to a statin does not reduce mortality but does expose to adverse effects, although these are not well known.
1 October 2019

Trials funded by drug companies: publication or publicity?

Pharmaceutical companies have a tight grip on the publication of the clinical study results that will allow them to obtain marketing authorisation for their products. A situation that is regrettable, but predictable.
1 October 2019

Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects

FEATURED REVIEW Erenumab (Aimovig°) is a monoclonal antibody that has been authorised in the European Union for the prevention of migraine attacks in patients who experience attacks on more than 4 days a month. Prescrire's editorial staff have weighed the available evidence to bring you an unbiased assessment of the drug's harm-benefit balance.
Full review (5 pages) available for download by subscribers.
1 September 2019

In the September edition of Prescrire International: sartan medicines contaminated by impurities which are probable carcinogens

FREE DOWNLOAD The exposure of patients all around the world and over a period of several years to impurities which are known to be carcinogenic, and which were present in commonly used medicines, shows that the systems intended to guarantee pharmaceutical quality need to be improved.
Full text available for free download.
1 September 2019

Carpal tunnel syndrome: sometimes drug-related

Carpal tunnel syndrome is sometimes caused by certain drugs, and disappears when the medication is stopped.
1 September 2019

New drugs: investing in more informative clinical trials

More informative clinical trials are more expensive, but that is the price of better care.
1 September 2019

Fluoroquinolones: use should be restricted due to severe adverse effects

Given the many and sometimes severe adverse effects of fluoroquinolone antibiotics, they should only be used for limited purposes.
1 September 2019

Psychotic episode: which oral neuroleptic to choose? A choice tailored to each patient, based on the adverse effect profiles of the options

FEATURED REVIEW Neuroleptic drugs have been widely used since the 1950s to treat psychotic episodes. When an oral neuroleptic appears justified for treating a psychotic episode in an adult, which drug should be chosen?
Full review (7 pages) available for download by subscribers.
1 July 2019

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90